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Abstract
Obesity, from early childhood onwards, is a common societal problem. The overconsumption of sweet, salty and high-fat
products are the main factors that cause excessive weight gain. It is therefore necessary to search for new drugs that affect satiety
centers and reduce the sense of hunger and caloric intake. It has been suggested that the blockade of 5-HT6 receptors may reduce
food intake, and since idalopirdine is a clinically tested, selective 5HT6 receptor antagonist, it was chosen to be examined in
animal models of obesity. The activity of idalopirdine was measured in the rat model of excessive eating. Animals were on a high
caloric diet that consisted of milk chocolate with nuts, cheese, salted peanuts and condensed milk. During a four-week exper-
iment, the rats had constant access to standard feed and water ad libitum. Idalopirdine was administered intraperitoneally at a dose
5 mg/kg b.w./day. To establish whether idalopirdine would effectively suppress the rebound hyperphagia that accompanies
refeeding, it was administered after a 20 h food deprivation period. Pica behavior was evaluated after the administration of
idalopirdine to confirm that the suppression of food intake was not caused by visceral illness. The effect of the four-week
treatment with idalopirdine on the amount of peritoneal adipose tissue, and on lipid and carbohydrate profiles in rats was also
examined. The statistical significance was calculated using the one-way ANOVA post-hoc Tukey Multiple Comparison Test or
the two-way ANOVA post-hoc Bonferroni Multiple Comparison Test. Idalopirdine significantly reduced caloric intake and
prevented the development of obesity in tested animals. Rats, that received idalopirdine, had a smaller amount of adipose tissue
in the peritoneum as well as lower glucose, triglyceride and cholesterol levels in comparison to the control group. Moreover, an
anorectic action was not caused by abnormalities of the gastrointestinal tract, such as nausea. The obtained results indicate that
idalopirdine reduces caloric intake and could be considered for further tests as a potential treatment of obesity.
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Introduction
The epidemic of obesity is mostly responsible for the increas-
ing prevalence of the metabolic syndrome (Rutigliano et al.
2017) and thus effective treatment of obesity still remains an
important aim of public health worldwide. Obesity, from early
childhood onwards, is a common societal problem (Zeyda and
Stulnig 2009). A very large group of children aged 10 are
either overweight, or already obese (WHO 2015). The over-
consumption of sweet, salty and high-fat products are the
main factors that cause obesity (WHO 2015). It is therefore
necessary to search for new drugs that affect satiety centers
and reduce the sense of hunger and caloric intake.
Idalopirdine is a potent and selective 5-HT6 receptor antag-
onist (Ki = 0.83 nM) (Arnt et al. 2010) developed by
Lundbeck and Otsuka Pharmaceuticals, as an adjunctive ther-
apy for the treatment of cognitive deficits associated with
Alzheimer’s disease. Mørk et al. (2017) indicated that
idalopirdine increased cortical levels of dopamine and nor-
adrenaline. As of October 2013, it is in phase III clinical trials
(Galimberti and Scarpini 2015; Wilkinson et al. 2014).
Idalopirdine has been proven to be safe and well tolerated at
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single doses of up to 360 mg in clinical pharmacology studies
(Ellen Schmidt, Lundbeck, Valby, Denmark, personal com-
munication) and at a daily dose of 30 mg thrice during
24 weeks of randomized, double-blind, placebo-controlled
phase II trials (LADDER) (Wilkinson et al. 2014). Besides
the promising procognitive effects, the 5-HT6 receptor block-
ade has been implicated in the reduction of food intake, body
weight, as well as visceral adiposity and insulin resistance
(Heal et al. 2008). 5-HT6 receptor antagonists block the
serotonin-dependent activation of γ-aminobutyric acid
(GABA) neurons, which results in a reduction of inhibitory
effects of GABA on pro-opiomelanocortin neurons in the ar-
cuate nucleus, with subsequent inhibition of hunger signal
induction (Sargent and Henderson 2011). Since idalopirdine
is the most advanced selective 5-HT6 antagonist in develop-
ment, it was selected by us for studying the effects on food
intake. We have recently shown that idalopirdine significantly
decreased food intake and the amount of peritoneal fat as well
as reduced the level of plasma triglycerides in obese animals
(Dudek et al. 2015). As a follow up, in the present study, we
tested the effect of idalopirdine on food intake and body
weight in the model of excessive eating (Western diet) in rats,
including the effect on the rebound hyperphagia. The per-
formed studies could constitute a premise for further preclin-
ical and clinical evaluation of idalopirdine as a potential treat-
ment of obesity.
Materials and methods
Animals
The experiments were carried out on male Wistar rats
weighting between 200 g and 230 g. The animals were housed
in plastic cages (3 rats per cage) at a constant room tempera-
ture of 22 ± 2 °C, with 12:12 h light/dark cycle. Water and
food were available ad libitum. Each control and experimental
group consisted of six to eight animals. All experiments were
conducted in accordance with the Guide to the Care and Use
of Experimental Animals and were approved by the Local
Ethics Committee for Experiments on Aminals of the
Jagiellonian University in Krakow (2013 and 2015, Poland;
approval numbers 136/2013 and 258/2015).
The influence of idalopirdine on body weight
and food and water intake in rats fed with palatable
diet (western-style diet) and normal diet
In order to determine the anorectic activity of idalopirdine, its
effect on caloric and water intake in the model of excessive
eating was assessed (Kotańska et al. 2017). Two groups of six
rats were fed during four weeks with a diet consisting of milk
chocolate with nuts, cheese, salted peanuts and 7% condensed
milk. Animals had access to standard food (Labofeed B,
Morawski Manufacturer Feed, Poland) and water ad libitum.
The palatable control group received intraperitoneally a
vehicle (5% 2-hydroxypropyl-beta-cyclodextrin) whereas
idalopirdine palatable group received 5 mg/kg b.w. of
idalopirdine in 5% 2-hydroxypropyl-beta-cyclodextrin.
Palatable diet contained: 100 g peanuts – 614 kcal; 100 ml
condensed milk – 131 kcal; 100 g milk chocolate with
hazelnuts – 195 kcal; 100 g Greek cheese – 270 kcal.
Two other groups of rats were on a standard diet (100 g
feed - 280 kcal). A vehicle (5% HP-beta-cyclodextrin) was
administered intraperitoneally to the control group, while
idalopirdine (5 mg/kg b.w./day) in 5% 2-hydroxypropyl-
beta-cyclodextrin was given to idalopirdine group.
The consumption of food and water was evaluated three
times per week and body weight of animals was measured
daily, immediately before administration of substances. On
the 29th day of the experiment, 20 min after intraperitoneal
administration of heparin (1000 j/rat) and thiopental (70 mg/
kg b.w.), plasma was collected from the left carotid artery and
peritoneal fat was weighed (Fig. 1).
Influence on acute feed consumption after 20-h feed
deprivation in rats (model of hyperphagia
after refeeding)
To establish whether idalopirdine would effectively suppress
the rebound hyperphagia that accompanies refeeding, the rats
were taught that they would have access to food for only 4 h
during the day. That procedure was implemented on the first,
second and third day of the experiment, while the animals
were given their feed at 9:30 AM and had it removed at
1:30 PM. On the 4th day, the feed was served at 9:30 AM
and remained in the cage until 1:30 PM of the 5th day. On the
6th day, the feed was served at 9:30 AM and remained until
1:30 PM. On the 7th day of the experiment, idalopirdine was
administered intraperitoneally at a dose of 5 mg/kg b.w.,
30 min before serving feed (9.00 AM). The control group
received only the vehicle. The amount of consumed feed
was evaluated every hour, starting at 10:30 AM until
1:30 PM and then after 24 h (Fig. 2).
Influence on visceral illness via measurement
of kaolin intake (Pica behavior)
To exclude the possibility that the suppression of food intake
by idalopirdine was caused by visceral illness, pica behavior
was evaluated. Themethodwas based on the works by Takeda
et al. (1993) and Yamamoto et al. (2002). The experiment
lasted five days. In addition to free access to feed, animals
had free access to the white kaolin. For the first few days,
the animals were accustomed to the presence of kaolin in their
cages. On the 4th day, either idalopirdine (5 mg/kg b.w.), a
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vehicle (negative control group), or a solution of CuSO4
(6 mg/kg b.w. - 1/3 LD50; LD50 = 18 mg/kg for a rat at this
route of administration; positive control group) was adminis-
tered intraperitoneally. The amount of consumed food, water
and kaolin was determined after 24 h. Moreover animals were
weighed before the administration of the compounds and 24 h
after.
Influence on lipid profile and glucose level in plasma
To determine the lipid profile and glucose level in plasma,
standard enzymatic and spectrophotometric tests
(Biomaxima S.A. Lublin, Poland) were carried out. The sub-
strate was decomposed with enzymes suitable to the relevant
product, which was then converted to a colored compound.
The coloration was proportional to the concentration. The ab-
sorbance was measured at a wavelength of 500 (glucose, tri-
glycerides, total cholesterol).
Data analysis and statistical procedures
Statistical calculations were carried out with GraphPad Prism
6 software. The presented results are the means ± S.E.M. The
statistical significance was calculated using the one-way anal-
ysis of variance (ANOVA) post-hoc Tukey Multiple
Comparison Test or the two-way ANOVA post-hoc
BonferroniMultiple Comparison Test. Differences considered
were statistically significant at: *, ^ p ≤ 0.05, **,^^ p ≤ 0.01,
***, ^^^ p ≤ 0.001.
Drugs, chemical reagents and other materials
Heparin was provided by Polfa Warszawa S.A. (Warsaw,
Poland), while thiopental sodium by Sandoz International
(Stryków, Poland) and 5% 2-hydroxypropyl-beta-
cyclodextrin by Sigma-Aldrich, USA.
Idalopirdine was synthesized in the Department of
Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian
University Medical College, Kraków, Poland according to
the procedure described previously (Pasternak and
Szymonifka 2009). The structure was confirmed by proton
and carbon nuclear magnetic resonance (1HNMR, 13CNMR)
obtained through a Varian BB 200 spectrometer using
tetramethylsilane (TMS) (0.00 ppm) in chloroform-d1. The
purity was established by ultra-performance liquid
chromatography-mass spectrometry (UPLC-MS) analysis at
>98%. The UPLC/MS system consisted of a Waters Acquity
UPLC, coupled to a Waters single quadrupole detector (SQD)
mass spectrometer. Chromatographic separations were carried
out using an Acquity UPLC Ethylene Bridged Hybrid (BEH)
C18 column, 2.1 × 100 mm and 1.7 μm particle size. The
column was maintained at 60 °C and eluted under the follow-
ing gradient conditions: 4 min, a linear gradient from 80 to
0.1% of eluent A at a flow rate of 0.5 ml/min. Eluent A: water/
formic acid (0.02%, v/v) and eluent B: methanol – acidic gra-
dient. Eluent A: water/formic acid/ammonia solution (0.01%/
0.1%, v/v/v) and Eluent B: methanol – alkaline gradient.
Results
Obesity induced with palatable diet
Animals fed with the palatable diet indicated significantly
higher weight gain than the group fed with the standard feed
(from day 8 of the experiment). On the 8th day, the difference
was 6.51%, whereas on the 28th day it was 14.82%.
Throughout the experiment, rats from the control group fed
with standard feed put on 55% of their initial weight, while
rats from the control group fed with a palatable feed had a
weight gain of 73.38%. Results are shown in Fig. 3.
Fig. 2 A schematic diagram of feeding scheme, compound
administration and measure points in model of influence on acute feed
intake after feed deprivation period model
Fig. 1 A schematic diagram of chronic administration of
idalopirdine in model of excessive eating. Idalopirdine (5 mg/kg b.w.)
was administered intrapiritoneally to rats for 28 consecutive days. Control
groups received 5% 2-hydroxypropyl-beta-cyclodextrin
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Effect of idalopirdine on body weight, caloric
and water intake
The animals fed with palatable feed and treated with
idalopirdine showed significantly less weight gain than rats
from the control group consuming a preferential feed. From
the 8th day of the experiment, a statistically significant differ-
ence in bodyweight between the groups was observed (on day
8–5.02% and on day 28–16.09%). Most importantly, the body
weight of rats treated with idalopirdine that had access to
preferential feed did not differ significantly from the body
weight of rats from the control group fed with a standard feed.
No effect on body weight was noticed in animals treated with
idalopirdine and those who consumed standard feed. Results
are shown in Fig. 3.
Idalopirdine administered intraperitoneally at the dose of
5 mg/kg b.w. significantly reduced the amount of consumed
calories by the animals on a palatable diet in comparison to the
ones of the control group. No differences were observed in
caloric intake from the group that had access only to the stan-
dard feed. Results are shown in Fig. 4.
There were no significant differences in water intake by
animals between groups fed with the same feed. On the other
hand, significantly less water consumption was noticed in the
case of animals fed with preferential feed. Results are shown
in Fig. 5.
Influence on acute feed consumption after 20-h feed
deprivation in rats
After 20 h of fasting, idalopirdine was administered 30 min
before eating. For the first two hours, the amount of consumed
feed was comparable to that consumed by rats from the
control group. On the third hour, slightly more feed was con-
sumed and later slightly less. The results were non-significant.
Results are shown in Fig. 6.
Effects on visceral illness via measurement of kaolin
intake (Pica behavior)
Animals that received idalopirdine intraperitoneally at dose of
5 mg/kg b.w. did not consume more kaolin compared to the
control group that received only the vehicle. The second con-
trol group, that was given CuSO4, had a significantly greater
intake of kaolin and a significantly lower intake of feed and
water. This was accompanied by body weight decrease.
Results are shown in Fig. 7.
Fig. 3 Effect of long-term administration of the 5-HT6 receptor an-
tagonist, idalopirdine, on body weight in male Wistar rats in the
model of excessive eating. Results are means ± SEM, n = 6. Multiple
comparisons of the vehicle-treated control group against the vehicle-
treated palatable control group (*) or idalopirdine-treated palatable
group against the vehicle-treated palatable control group (^) were
calculated using the two-way ANOVA, post-hoc Benferroni test.
Significant differences are denoted by *, ^ p < 0.05; **, ^^ p < 0.01;
***, ^^^ p < 0.001
Fig. 4 Effect of long-term administration of the 5-HT6 receptor an-
tagonist, idalopirdine, on food intake inmaleWistar rats in themodel
of excessive eating. Results are means ± SEM, data for three animals
reared together. Multiple comparisons against the vehicle-treated control
group (*) or against the vehicle-treated palatable control group (^) were
calculated using the two-way ANOVA, post-hoc Bonferroni test.
Significant differences are denoted by *, ^ p < 0.05, **, ^^ p < 0.01,
***, ^^^ p < 0.001
Fig. 5 Effect of long-term administration of the 5-HT6 receptor an-
tagonist, idalopirdine, on water intake in male Wistar rats in the
model of excessive eating. Results are means ± SEM, data for three
animals reared together. Multiple comparisons against the vehicle-
treated palatable control group (*) were calculated using the two-way
ANOVA, post-hoc Bonferroni test. Significant differences are denoted
by * p < 0.05, ** p < 0.01, *** p < 0.001
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Influence of the 4-week chronic treatment
with idalopirdine on the amount of peritoneal
adipose tissue and lipid and carbohydrate profiles
in rats
Animals consuming palatable feed had statistically signifi-
cantly more fat in peritonea. The group, which received the
tested compound, had a significantly lower amount of fat in
the peritonea compared to the obese rats. The results are
shown in Fig. 8.
Moreover, the level of glucose, triglyceride and cholesterol
in blood was higher in rats on the palatable diet than on the
standard diet. Rats treated for four weeks with idalopirdine
and fed with a palatable diet had a significantly lower level
of glucose, triglycerides and cholesterol in plasma in compar-
ison to the control group fed with the palatable diet. The re-
sults are shown in Fig. 9.
Discussion
Idalopirdine is a selective 5-HT6 receptor antagonist, which is
being tested in phase III clinical trials as a potential treatment
of cognitive deficits in Alzheimer’s disease (Galimberti and
Scarpini 2015; Wilkinson et al. 2014). Numerous reports have
indicated that the 5-HT6 receptor antagonists, from different
chemical classes, reduce food intake and could be considered
as potential treatment of obesity (Heal et al. 2008). However,
it is highly unlikely, that a drug candidate for Alzheimer’s
disease would be clinically tested as an anti-obesity treatment,
without previous preclinical evidence suggesting such an ac-
tivity. To the best of our knowledge, so far there has been no
preclinical evaluation of idalopiridine in the animal model of
Fig. 7 Effect of one
administration of the 5-HT6
receptor antagonist,
idalopirdine, on kaolin intake
(a), food intake (b), water intake
(c) and body weight (d) in male
Wistar rats in the model of pica
behavior. Results are means ±
SEM, data for two animals reared
together, n = 6. Multiple
comparisons against the vehicle-
treated control group (*) were
calculated using the two-way
ANOVA, post-hoc Bonferroni
test. Significant differences are
denoted by * p < 0.05, **
p < 0.01, *** p < 0.001
Fig. 8 Weight of peritoneal fat after long-term administration of the
5-HT6 receptor antagonist – idalopirdine in male Wistar rats in the
model of excessive eating. Results are means ± SEM, n = 6. Multiple
comparisons against the vehicle-treated control group (*) or against the
vehicle-treated palatable control group (^) were calculated using the two-
way ANOVA, post-hoc Bonferroni test. Significant differences are
denoted by ** p < 0.01, ^^^ p < 0.001
Fig. 6 Effect of one administration of the 5-HT6 receptor antagonist,
idalopirdine, on food intake in male Wistar rats in the model of
refeeding hyperphagia. Results are means ± SEM, data for two
animals reared together, n = 6. Multiple comparisons against the
vehicle-treated control group were calculated using the two-way
ANOVA, post-hoc Bonferroni test
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excessive eating, although its mechanism of action indicates
potential influence on the reduction of food intake. Our goal
was therefore to provide a basis for further, extended preclin-
ical and clinical testing of idalopirdine in that indication.
As a result of the present study, we found that idalopirdine
significantly reduced caloric intake and prevented the devel-
opment of obesity in tested animals.
In the model of excessive eating from the 8th day of exper-
iment, the animals that consumed the palatable diet weighed
significantly more than the animals that ate only the standard
feed. During the experiment, the difference in weight in-
creased significantly, highlighting how quickly and effectively
obesity can develop in the presence of an unlimited source of
highly caloric products, which animals prefer to eat. An in-
crease in the amount of body fat, blood glucose, triglycerides
and cholesterol was also observed. Animals fed with
preferential feed and treated with idalopirdine consumed sig-
nificantly less calories than the control group fed with prefer-
ential feed and gained less weight than the untreated animals.
Similar results were previously obtained in a model of obesity
induced through the administration of high-fat feed. It was
observed that obese animals ate fewer calories and lost weight
after receiving idalopirdine (Dudek et al. 2015).
In the normally fed, non-obese animals, idalopiridine did
not disrupt body weight gain, indicating no risk of such side
effects for normal weight conditions. A decrease in the body
weight of animals, below normal values as well as a reduction
in the consumption of a normal diet could be considered as an
unacceptable side effect, however, in the present study this
was not the case. This observation is in line with clinical
results, indicating no weight loss in non-obese patients treated
with idalopirdine (Wilkinson et al. 2014).
Fig. 9 Effects of long-term administration of the 5-HT6 receptor an-
tagonist, idalopirdine, on plasma: glucose (a), triglyceride (b), and
total cholesterol (c) levels in male Wistar rats in the model of exces-
sive eating. Results are means ± SEM, n = 6. Concentrations in plasma:
mmol/l. Comparisons against the vehicle-treated control group (*) or
against the vehicle-treated palatable control group (^)were calculated
using the one-way ANOVA, post-hoc Tukey test. Significant
differences are denoted by *, ^ p < 0.05, ^^ p < 0.01
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Furthermore, administration of idalopirdine in animals that
had access to excess calories, decreased the amount of fat in
the peritoneum, as well as significantly lowered plasma glu-
cose, triglyceride and cholesterol levels, in comparison to the
control group fed with similar feed. The observed changes in
biochemical parameters were evidently associated with a de-
crease in excessive caloric intake.
Food consumption in rats and mice can also be decreased
through various factors including stress, sickness, sedation or
drug-induced toxicity and not only through the enhancement
of satiety or other specific mechanisms (Vickers et al. 2011).
Dudek et al. (2015) showcased that idalopirdine did not sig-
nificantly affect spontaneous activity of animals that remain
permanently under standard conditions in cages. Therefore, it
should be assumed that the reduction of food intake observed
in this study were not due to sedation. Moreover, if that were
the case, a decrease in food intake in the group fed with stan-
dard feed would also be observed.
Some drugs may reduce food intake by producing gastroin-
testinal malaise, which is difficult to detect in animal behavior.
Rats and mice lack the emetic response, which distinguishes
them from humans. However, the persistent eating of inert sub-
stances by rodents can be used to evaluate illness-response be-
havior analogous to vomiting in other species; this behavior is
called pica (Vickers et al. 2011; Takeda et al. 1993; Yamamoto
et al. 2002). In the present study, animals also had access to
kaolin clay. After being administered idalopirdine, rats did not
consume the clay, which proved that disorders of the gastroin-
testinal tract, such as visceral irritation or nausea, did not occur.
The consumption of kaolin clay, food and water did not differ
significantly in the group administered with idalopirdine, com-
pared to the negative control group. On the other hand, CuSO4,
used as a positive control in this test, extensively reduced the
food and water intake and significantly increased the consumed
amount of kaolin clay, indicating the stomach upset.
The effect of a single dose of the tested compound on the
amount of ingested food is often used as a screening of poten-
tial food intake reduction (Vickers et al. 2011). Such activity
can be observed after a single administration of clinically ac-
tive substances such as: d-fenfluramine, sibutramine,
rimonabant or lorcaserin (Jackson et al. 1997; Colombo et al.
1998; Neill and Cooper 1989; Smith et al. 2008). Animals used
in such an experiment are not required to be obese (Vickers
et al. 2011). The present study included an experiment that
determined the influence of idalopirdine on rebound hyperpha-
gia which accompanied refeeding. The results were established
after a single administration of idalopirdine to the fasted ani-
mals, which were taught that the feed would be provided only
for a limited time. Idalopirdine showed the influence on the
amount of food intake, but it was not statistically significant.
Although the differences in food consumption that occurred in
the 3rd, 4th and 24th hour of feed availability were not statis-
tically significant, they confirm that the tested compound
affects nutritional behavior. It is possible that the 5HT6 receptor
antagonists are incapable of inducing statistically significant
effect in such an experiment after a single administration, just
as they actually do not affect the amount of food intake after a
single administration, without application of the model of con-
trolled fasting (Heal et al. 2008). However, due to the special
feeding scheme required prior to administration of the com-
pound, it is not feasible to carry out the same experiment after
repeated administration.
Conclusion
In the present study we showed that idalopiridne, a selective 5-
HT6 receptor antagonist, tested in phase III clinical trials as a
cognitive enhancer in Alzheimer’s disease, is able to reduce
caloric intake and prevent the development of obesity in the
model of excessive eating. The effect was proven not to be
related to gastrointestinal malaise or sedation, testifying for its
specificity. Together with the previously shown anorectic ef-
fects of idalopirdine in obese animals (Dudek et al. 2015), the
present findings constitute an important prerequisite for fur-
ther preclinical and clinical investigation of idalopirdine as
potential anti-obesity agent.
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